Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 05, 2017 07:00 ET | Source: Summit Therapeutics PLC

Summit Announces Positive Top-Line Data From an Exploratory Phase 2 Clinical Trial Supporting Ridinilazole as a Highly Selective Antibiotic for the Treatment of CDI

OXFORD, United Kingdom, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
June 20, 2016 12:30 ET | Source: Summit Therapeutics PLC

Summit’s Ridinilazole Preserves Microbiome During Treatment of C. Difficile Infection

Microbiome-Sparing Action of Ridinilazole associated with Superiority over Vancomycin in Sustained Clinical Response Rate OXFORD, United Kingdom, June 20, 2016 (GLOBE NEWSWIRE) -- Summit...